| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Ginsenoside Ra1 targets protein tyrosine kinase (PTK). It inhibits PTK activation induced by hypoxia/reoxygenation (H/R). By inhibiting PTK, it may have effects on cell signaling pathways involved in ischemia-reperfusion injury and other conditions.
|
|---|---|
| ln Vitro |
In vitro, Ginsenoside Ra1 shows significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R). Quantitative IC50 values for its effects on PTK activation are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo activity data for Ginsenoside Ra1 is limited in publicly available literature. As an inhibitor of PTK activation induced by H/R, it may have potential for protecting against ischemia-reperfusion injury. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free assays, the PTK inhibitory activity of Ginsenoside Ra1 can be measured using a standard kinase activity assay. The compound is incubated with a purified protein tyrosine kinase and a peptide substrate in the presence of ATP. The phosphorylation of the substrate is measured using radioactive or fluorescence-based methods. The IC50 for PTK inhibition is calculated from a dose-response curve.
|
| Cell Assay |
For in vitro cellular assays, the PTK inhibitory activity of Ginsenoside Ra1 can be assessed in cells subjected to hypoxia/reoxygenation. Cells are treated with various concentrations of the compound, and PTK activation is measured by Western blot using phospho-specific antibodies. The inhibition of PTK activation is quantified.
|
| Animal Protocol |
For in vivo studies, Ginsenoside Ra1 could be administered orally or intraperitoneally in animal models of ischemia-reperfusion injury, such as myocardial infarction or stroke. Endpoints include infarct size, functional recovery, and markers of tissue damage.
|
| ADME/Pharmacokinetics |
Ginsenoside Ra1 (CAS 83459-41-0) has a molecular formula of C58H98O26 and a molecular weight of 1211.38 g/mol. Appearance: typically a powder. Solubility: DMSO and other organic solvents. Storage: typical for ginsenosides (desiccated, protected from light, -20°C). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural ginsenoside, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development.
|
| References | |
| Additional Infomation |
Ginsenoside Ra1 is a triterpenoid saponin.
Ginsenoside Ra1 is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying PTK signaling and ischemia-reperfusion injury. Its mechanism of action involves inhibition of PTK activation induced by hypoxia/reoxygenation. It is a natural product from Panax ginseng. No clinical trials have been reported. |
| Molecular Formula |
C58H98O26
|
|---|---|
| Molecular Weight |
1211.3831
|
| Exact Mass |
1210.63
|
| CAS # |
83459-41-0
|
| PubChem CID |
100941542
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.2
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
84
|
| Complexity |
2210
|
| Defined Atom Stereocenter Count |
33
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@H](CO8)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O)O)O)O)O)C
|
| InChi Key |
KVMXBSSOCCPAOR-WWJNHZDPSA-N
|
| InChi Code |
InChI=1S/C58H98O26/c1-24(2)10-9-14-58(8,84-52-47(74)42(69)39(66)30(81-52)22-76-49-45(72)40(67)31(23-77-49)80-50-44(71)36(63)27(62)21-75-50)25-11-16-57(7)35(25)26(61)18-33-55(5)15-13-34(54(3,4)32(55)12-17-56(33,57)6)82-53-48(43(70)38(65)29(20-60)79-53)83-51-46(73)41(68)37(64)28(19-59)78-51/h10,25-53,59-74H,9,11-23H2,1-8H3/t25-,26+,27+,28+,29+,30+,31-,32-,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43-,44+,45+,46+,47+,48+,49+,50-,51-,52-,53-,55-,56+,57+,58-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-17-[(2S)-2-[(2S,3R,4S,5S,6R)-6-[[(2S,3R,4R,5S)-3,4-dihydroxy-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-methylhept-5-en-2-yl]-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~82.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8255 mL | 4.1275 mL | 8.2550 mL | |
| 5 mM | 0.1651 mL | 0.8255 mL | 1.6510 mL | |
| 10 mM | 0.0826 mL | 0.4128 mL | 0.8255 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
